Ganirelix Acetate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ganirelix Acetate |
| DrugBank ID | DB06785 |
| Brand Names (EU) | Ganirelix Gedeon Richter |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hypertrichosis (disease) | 99.98% | DL |
| 2 | Ambras type hypertrichosis universalis congenita | 99.98% | DL |
| 3 | malformation syndrome with odontal and/or periodontal component | 99.97% | DL |
| 4 | syndrome with a Dandy-Walker malformation as major feature | 99.97% | DL |
| 5 | isolated genetic hair shaft abnormality | 99.97% | DL |
| 6 | familial male-limited precocious puberty | 99.85% | DL |
| 7 | persistent fetal circulation syndrome | 99.80% | DL |
| 8 | aromatase excess syndrome | 99.80% | DL |
| 9 | centra precocious puberty 1 | 99.75% | DL |
| 10 | familial isolated trichomegaly | 99.75% | DL |
| 11 | pelvic organ prolapse | 99.62% | DL |
| 12 | female genital tuberculosis | 99.60% | DL |
| 13 | physiological sexual disorder | 99.60% | DL |
| 14 | idiopathic central precocious puberty | 99.59% | DL |
| 15 | dysplasia of cervix | 99.50% | DL |
| 16 | X-linked congenital generalized hypertrichosis | 99.50% | DL |
| 17 | precocious puberty, central, 2 | 99.45% | DL |
| 18 | diffuse cutaneous mastocytosis | 99.42% | DL |
| 19 | genetic alopecia | 99.38% | DL |
| 20 | precocious puberty | 99.31% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.